1990
A Phase 1 Study of Ribavirin in Human Immunodeficiency Virus-Infected Patients
Roberts R, Jurica K, Meyer W, Paxton H, Makuch R. A Phase 1 Study of Ribavirin in Human Immunodeficiency Virus-Infected Patients. The Journal Of Infectious Diseases 1990, 162: 638-642. PMID: 2117625, DOI: 10.1093/infdis/162.3.638.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsPhase 1 studyDaily dosesAdverse reactionsTreatment groupsHuman immunodeficiency virus-infected patientsPatients' peripheral blood mononuclear cellsHIV surrogate markersT lymphocyte subsetsVirus-infected patientsClinical adverse reactionsAnti-HIV effectDemonstrable beneficial effectsHuman immunodeficiency virusBlood mononuclear cellsOral ribavirinP24 antigenemiaLymphocyte subsetsTotal lymphocytesSerum betaImmunodeficiency virusLymphocyte markersMononuclear cellsLymphocyte populationsSurrogate markerA multicenter clinical trial of oral ribavirin in HIV-infected patients with lymphadenopathy. The Ribavirin-LAS Collaborative Group.
Roberts R, Dickinson G, Heseltine P, Leedom J, Mansell P, Rodriguez S, Johnson K, Lubina J, Makuch R. A multicenter clinical trial of oral ribavirin in HIV-infected patients with lymphadenopathy. The Ribavirin-LAS Collaborative Group. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1990, 3: 884-92. PMID: 1974628.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdministration, OralAdolescentAdultCD4 AntigensCD4-Positive T-LymphocytesDose-Response Relationship, DrugDouble-Blind MethodEvaluation Studies as TopicHumansImmunoblastic LymphadenopathyLeukocyte CountMaleMiddle AgedMulticenter Studies as TopicRandomized Controlled Trials as TopicRibavirinRibonucleosidesConceptsOral ribavirinActive treatmentBaseline CD4 cell countMajor protocol violationsCD4 cell countPlacebo-controlled trialMulticenter clinical trialSignificant differencesPlacebo patientsPlacebo groupPlacebo treatmentStudy entryTreat analysisWashout periodDaily dosesClinical trialsKaposi's sarcomaProtocol violationsMedical CenterTreatment superiorityTreatment groupsPlaceboRibavirinPatientsOverall significant difference
1979
EFFECTS OF THYMOSIN IN VITRO IN CANCER PATIENTS AND CORRELATION WITH CLINICAL COURSE AFTER THYMOSIN IMMUNOTHERAPY
Chretien P, Lipson S, Makuch R, Kenady D, Cohen M. EFFECTS OF THYMOSIN IN VITRO IN CANCER PATIENTS AND CORRELATION WITH CLINICAL COURSE AFTER THYMOSIN IMMUNOTHERAPY. Annals Of The New York Academy Of Sciences 1979, 332: 135-147. PMID: 316979, DOI: 10.1111/j.1749-6632.1979.tb47107.x.Peer-Reviewed Original ResearchSerum glycoproteins in head and neck squamous carcinoma Correlations with tumor extent, clinical tumor stage, and T-cell levels during chemotherapy
Wolf G, Chretien P, Elias E, Makuch R, Baskies A, Spiegel H, Weiss J. Serum glycoproteins in head and neck squamous carcinoma Correlations with tumor extent, clinical tumor stage, and T-cell levels during chemotherapy. The American Journal Of Surgery 1979, 138: 489-500. PMID: 90464, DOI: 10.1016/0002-9610(79)90407-0.Peer-Reviewed Original ResearchConceptsΑ1-acid glycoprotein levelsT cell levelsTumor stageAcute phase proteinsUntreated patientsSerum levelsTumor extentCellular immunityImmune reactivitySquamous carcinomaPhase proteinsGlycoprotein levelsSpecific acute phase proteinsCompletion of chemotherapyClinical tumor stageChronic cigarette smokersΑ1-antitrypsin levelsΑ1-antitrypsinCellular immune parametersNeck squamous carcinomaPreoperative chemotherapyRecurrent carcinomaAlbumin levelsControl patientsRegional metastasesThymosin immunotherapy in patients with small cell carcinoma of the lung. Correlation of in vitro studies with clinical course
Lipson S, Chretien P, Makuch R, Kenady D, Cohen M. Thymosin immunotherapy in patients with small cell carcinoma of the lung. Correlation of in vitro studies with clinical course. Cancer 1979, 43: 863-870. PMID: 218717, DOI: 10.1002/1097-0142(197903)43:3<863::aid-cncr2820430313>3.0.co;2-5.Peer-Reviewed Original ResearchConceptsTotal T cellsPretreatment CEA levelsT cellsCEA levelsClinical courseCellular immunityTumor responsePretreatment levelsCarcinoembryonic antigenAdministration of thymosinIntensive chemotherapy programsPeripheral blood levelsSmall cell carcinomaDuration of responseOverall tumor responseThymus-dependent lymphocytesLarger patient populationType of treatmentP groupMechanism of actionComplete remissionT60 groupChemotherapy programBronchogenic carcinomaImmune defects
1978
Thymosin in cancer patients: in vitro effects and correlations with clinical response to thymosin immunotherapy.
Chretien P, Lipson S, Makuch R, Kenady D, Cohen M, Minna J. Thymosin in cancer patients: in vitro effects and correlations with clinical response to thymosin immunotherapy. Journal Of The National Cancer Institute 1978, 62: 1787-90. PMID: 215307.Peer-Reviewed Original Research